B · Normal
[Eli Lilly’s third-quarter revenue of US$24.40 billion was higher than market expectations] On October 29, Eli Lilly’s third-quarter revenue was US$24.40 billion, compared with US$22.61 billion expected; adjusted earnings per share were US$7.48, compared with US$6.26 expected. Eli Lilly's full-year revenue outlook is US$91 billion to US$92 billion, compared with the previous forecast of US$85 billion to US$87 billion.
Comments